Related Experiment Videos

Should beta-blockers be used to control hypertension in people with chronic kidney disease?

Peter D Hart1, George L Bakris

  • 1Division of Nephrology, Department of Medicine, Cook County Hospital, Chicago, IL, USA.

Seminars in Nephrology
|September 18, 2007
PubMed

Insights

Sympathetic nervous system activation is common in chronic kidney disease (CKD). Vasodilating beta-blockers like carvedilol offer cardiorenal protection in CKD patients with hypertension.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Sympathetic nervous system overactivation is prevalent in chronic kidney disease (CKD), contributing to hypertension and adverse cardiovascular outcomes.
  • Beta-blockers are antihypertensives with varying effects on renal function; cardioselective agents show limited renal benefit compared to renin-angiotensin-aldosterone system blockers.
  • Newer vasodilating beta-blockers, such as carvedilol, possess unique properties due to alpha1-blocking activity, influencing renal hemodynamics differently.

Purpose of the Study:

  • To evaluate the distinct renal hemodynamic and functional effects of vasodilating beta-blockers, specifically carvedilol, in hypertensive patients with and without impaired kidney function.
  • To assess the potential of carvedilol in retarding albuminuria progression and providing cardiorenal protection in CKD patients.

Main Methods:

  • The study focuses on analyzing the impact of carvedilol on renal vascular resistance, glomerular filtration rate, and renal blood flow.
  • Evaluation of carvedilol's effect on albuminuria progression and overall cardiorenal outcomes in specific patient cohorts.

Main Results:

  • Carvedilol demonstrated a decrease in renal vascular resistance.
  • The drug prevented reductions in glomerular filtration rate and renal blood flow in hypertensive patients, irrespective of kidney function.
  • Carvedilol showed potential in slowing albuminuria progression.

Conclusions:

  • Carvedilol exhibits favorable effects on renal hemodynamics and function in hypertensive patients, including those with CKD.
  • The vasodilating beta-blocker carvedilol may offer significant cardiorenal protection, particularly in CKD patients with hypertension and heart failure.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...